The Center is also focused on the development of new recombinant coagulation factors (such as FVII, FVIII and FIX) with improved properties. The platform to produce these new recombinant proteins is based on human cell lines that are able to secrete proteins with the same glycosylation pattern found in the plasma derived coagulation factors. Moreover we are developing synthetic FVIII cDNA containing mutations that reduce the immunogenicity of the human recombinant protein.
